VYGR - Voyager Therapeutics Inc. (VYGR) Q1 2024 Earnings Call Transcript

2024-05-14 04:43:07 ET

Voyager Therapeutics, Inc. (VYGR)

Q1 2024 Earnings Conference Call

May 13, 2024, 04:30 PM ET

Company Participants

Trista Morrison - Chief Corporate Affairs Officer

Alfred Sandrock - CEO

Todd Carter - Chief Scientific Officer

Toby Ferguson - Chief Medical Officer

Robin Swartz - COO and Principal Financial Officer

Conference Call Participants

Mehdi Goudarzi - Truist Securities

Jack Allen - Baird

Patrick Trucchio - H.C. Wainwright & Co.

Philip Nadeau - TD Cowen

Ry Forseth - Guggenheim Securities

David Hoang - Citigroup

Sumant Kulkarni - Canaccord Genuity

Yanan Zhu - Wells Fargo Securities

Laura Chico - Wedbush

Joon Lee - Truist Securities

Presentation

Operator

Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note that today's conference is being recorded. A replay of today's call will be available on the Investors section of the company's website approximately two hours after completion of this call.

I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer.

Trista Morrison

Thank you, and good afternoon. We issued our first quarter 2024 financial results press release this afternoon. The press release and 10-Q are available on our website. Joining me on today's call are Dr. Al Sandrock, our Chief Executive Officer; Dr. Toby Ferguson, our Chief Medical Officer; and Dr. Todd Carter, our Chief Scientific Officer. We will also be joined for the Q&A portion of the call by our Chief Operating Officer and Principal Financial Officer, Robin Swartz.

Before we get started, I would like to remind everyone that during this call, Voyager representatives may make forward-looking statements, as noted in Slide 2 of today's deck. These statements are based on our current expectations and beliefs. They are subject to risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings, which are available on our website.

And now I will turn the call over to Al.

Alfred Sandrock

Thank you, Trista, and good afternoon, everyone.

Please turn to Slide 3. I'd like to start by thanking the Voyager team for their dedication to creating transformative genetic medicines. We made tremendous progress advancing these medicines in the first quarter. We just announced that we have obtained IND clearance for our anti-tau antibody, VY-TAU01, for Alzheimer's disease, and we expect to announce the dosing of the first subject in a single ascending dose trial in healthy volunteers in the coming week or so.

Our gene therapy pipeline also advanced during the quarter with development candidates selected in the GBA1 and Friedreich's Ataxia programs partnered with Neurocrine. These programs, along with our wholly owned SOD1-ALS program, are advancing towards IND filings in 2025....

For further details see: